BDR Pharma Expands CDMO Business with Acme Formulation Acquisition
BDR Pharma acquires a controlling stake in Acme’s oral formulations business to expand its CDMO capabilities and strengthen its women’s healthcare portfolio.
freepik
Opinions expressed by Entrepreneur contributors are their own.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
BDR Pharma has agreed to acquire a controlling stake in the oral solid formulations business of Acme Formulation Private Limited and its subsidiaries from existing shareholders led by private equity firm PAG. The acquisition will strengthen BDR Pharma’s contract development and manufacturing organisation (CDMO) platform and expand its presence across key therapeutic segments.
The deal aligns with BDR Pharma’s growth strategy in oncology, critical care and women’s healthcare. It will add manufacturing capabilities in thyroid products, female sex hormones and general pharmaceutical formulations, while creating opportunities to expand its international product portfolio.
BDR Pharma also plans to leverage Acme’s USFDA-approved manufacturing facilities alongside its recently acquired portfolio of Abbreviated New Drug Applications (ANDAs) and products for the US market. The additional infrastructure and capacity could help the company gradually commercialise its own products and strengthen its presence across the pharmaceutical value chain.
Dharmesh Shah, Chairman and Managing Director of BDR Pharma, said the acquisition would strengthen the company’s CDMO platform and add differentiated capabilities as it continues to expand its global presence.
Following the transaction, PAG and Viral Shah will retain full ownership of Immacule, a sterile injectable-focused contract manufacturing business. The company will now focus on scaling Immacule’s operations and developing it into a leading global sterile injectables platform.
Immacule operates two manufacturing facilities in Nalagarh, Himachal Pradesh, with a combined investment of approximately $100 million and around 750 employees. Its recently commissioned second facility has increased annual manufacturing capacity to more than 200 million units, with dedicated lines for vials, ophthalmic products, pre-filled syringes, cartridges and oncology products.
The company serves more than 30 Indian and international pharmaceutical companies and supplies over 50 globally approved products, with a focus on the US market.
Nikhil Srivastava, Partner and Co-Head of Private Equity at PAG, said BDR Pharma was well-positioned to take Acme’s oral formulations business into its next phase of growth. Viral Shah, Founder of Acme and Managing Director of Immacule, added that BDR Pharma’s expertise in complex medicines would help expand the product offerings available to Acme’s CMO and CDMO customers.o3 Capital acted as the exclusive financial adviser to BDR Pharma on the transaction.
BDR Pharma has agreed to acquire a controlling stake in the oral solid formulations business of Acme Formulation Private Limited and its subsidiaries from existing shareholders led by private equity firm PAG. The acquisition will strengthen BDR Pharma’s contract development and manufacturing organisation (CDMO) platform and expand its presence across key therapeutic segments.
The deal aligns with BDR Pharma’s growth strategy in oncology, critical care and women’s healthcare. It will add manufacturing capabilities in thyroid products, female sex hormones and general pharmaceutical formulations, while creating opportunities to expand its international product portfolio.
BDR Pharma also plans to leverage Acme’s USFDA-approved manufacturing facilities alongside its recently acquired portfolio of Abbreviated New Drug Applications (ANDAs) and products for the US market. The additional infrastructure and capacity could help the company gradually commercialise its own products and strengthen its presence across the pharmaceutical value chain.
